News

MEMO THERAPEUTICS AG APPOINTS ERIK VAN DEN BERG AS CHIEF EXECUTIVE OFFICER

Schlieren / Zurich, Switzerland – November 16, 2023 – Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO). Mr. van den Berg joins MTx with over 25 years’ industry experience and proven track record in leading...

read more

Specialist Seminar Schlieren: Using single cell analysis to guide cell therapy development in cancer

When: Tuesday, December 5th, at 16:00h. Where: Seminar room L121/123, Wagistrasse 12, 6th floor Presenter: Sebastian Kobold, Ludwig-Maximilians-Universität München, Germany  Sebastian Kobold, M.D. is a professor of experimental immunooncology, head of the immunopharmacology group, and deputy director of the division of clinical pharmacology at the University Hospital of Munich. He has received, among...

read more

Natural Selection in Antibody R&D: Survival of the Fittest

Date and time: Thu, Dec 7, 2023 11:30 AM - 12:30 PM CET Location: Dinaqor - Conference Room, Wagistrasse 25, 8952 Schlieren Rapid Novor is at the forefront of accelerating therapeutic antibody discovery with our cutting-edge REpAb® platform. Based in Canada, our expertise lies in de novo protein sequencing, advancing the capabilities...

read more